Consensus Regeneron Pharmaceuticals, Inc.

Stocks

REGN

US75886F1075

Pharmaceuticals

Market Closed - Nasdaq 23:00:00 28/10/2026 +03			5-day change	1st Jan Change
813.27 ^USD	-0.35%		+0.94%	+5.36%

10-28	Evercore ISI Adjusts Price Target on Regeneron Pharmaceuticals to $850 From $900	MT
10-28	Canaccord Genuity Adjusts Price Target on Regeneron Pharmaceuticals to $922 From $875	MT

Evolution of the Average Target: Regeneron Pharmaceuticals, Inc.

Evolution of the Target Price: Regeneron Pharmaceuticals, Inc.

Changes in Analyst Recommendations: Regeneron Pharmaceuticals, Inc.

592c72c2a698ea50cf3.0p_GDG-leYTfqi1gQY7V4Itw7VHMxVGGrBlsmlJLTTY.m-_zSTeQCcu2_FQpI_6g08cGphacjWfu5mMg7CEiF3zr3YpGC8ANzLDnGQ~5b309ed9eb32557487abbf22809f63ac

Analysts' recommendations: Regeneron Pharmaceuticals, Inc.

10-28	Evercore ISI Adjusts Price Target on Regeneron Pharmaceuticals to $850 From $900	MT
10-28	Canaccord Genuity Adjusts Price Target on Regeneron Pharmaceuticals to $922 From $875	MT
10-22	Evercore ISI Adjusts Price Target on Regeneron Pharmaceuticals to $900 From $850	MT
10-21	TD Cowen Adjusts Price Target on Regeneron Pharmaceuticals to $980 From $960	MT
10-15	Regeneron Pharmaceuticals Shares Rise After UBS Upgrade	MT
10-15	UBS Upgrades Regeneron Pharmaceuticals to Buy From Neutral, Adjusts Price Target to $978 From $660	MT
10-15	Goldman Sachs Adjusts Price Target on Regeneron Pharmaceuticals to $968 From $972	MT
10-08	RBC Raises Price Target on Regeneron Pharmaceuticals to $810 From $737, Keeps Sector Perform Rating	MT
10-07	Morgan Stanley Adjusts Price Target on Regeneron Pharmaceuticals to $779 From $758	MT
10-07	Berenberg Says Sanofi, Regeneron's Expanded Immunology Collaboration Extends 'Dominance' in Atopic Diseases	MT
10-06	JPMorgan Adjusts PT on Regeneron Pharmaceuticals to $950 From $900, Keeps Overweight Rating	MT
10-02	Jefferies Raises Regeneron Pharmaceuticals Price Target to $930 From $870, Maintains Buy Rating	MT
10-01	Jefferies Raises Regeneron Pharmaceuticals Price Target to $930 From $870	MT
10-01	Argus Upgrades Regeneron Pharmaceuticals to Buy From Hold, Price Target is $850	MT
09-29	Regeneron Needs 'Better' Terms in Sanofi Renegotiation, RBC Says	MT
09-24	Regeneron Approaching Incremental Catalysts Like Upcoming Olatorepatide Data Readout, RBC Says	MT
09-09	BMO Capital Adjusts Price Target on Regeneron Pharmaceuticals to $920 From $800, Keeps Outperform Rating	MT
09-01	Regeneron Seen Weighing Expanded Sanofi Deal, RBC Says	MT
08-17	Leerink Partners Adjusts PT on Regeneron Pharmaceuticals to $824 From $641, Maintains Market Perform Rating	MT
08-14	Bernstein Adjusts PT on Regeneron Pharmaceuticals to $756 From $753, Maintains Market Perform Rating	MT
07-31	Regeneron Pharmaceuticals' Robust Q2 Sales Amid Limited Spend Increases to Help Ramp H2 Margins, RBC Says	MT
07-31	RBC Raises Price Target on Regeneron Pharmaceuticals to $737 From $696, Keeps Sector Perform Rating	MT
07-31	Baird Adjusts Price Target on Regeneron Pharmaceuticals to $761 From $742, Maintains Neutral Rating	MT
07-31	Wells Fargo Adjusts PT on Regeneron Pharmaceuticals to $750 From $700, Maintains Equalweight Rating	MT
07-31	Morgan Stanley Adjusts PT on Regeneron Pharmaceuticals to $758 From $730, Keeps Equalweight Rating	MT

More recommendations

Biopharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	REGENERON PHARMACEUTICALS, INC.					+6.28%
	ELI LILLY AND COMPANY					+4.04%
	JOHNSON & JOHNSON					+3.97%
	ABBVIE INC.					-1.12%
	ROCHE HOLDING AG					-3%
	MERCK & CO., INC.					+12.65%
	NOVARTIS AG					-3.77%
	ASTRAZENECA PLC					+23.18%
	AMGEN INC.					-11.3%
	GILEAD SCIENCES, INC.					+0.7%
	Average					+3.16%
	Weighted average by Cap.					+3.12%